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Abstract
Background: Dengue virus (DV) infection is one of the most important mosquito-borne diseases in the tropics. Recently, the
severe forms, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), have become the leading cause of death
among children in Southern Vietnam. Protective and/or pathogenic T cell immunity is supposed to be important in the
pathogenesis of DHF and DSS.
Methodology/Principal Findings: To identify HLA alleles controlling T cell immunity against dengue virus (DV), we
performed a hospital-based case control study at Children’s Hospital No.2, Ho Chi Minh City (HCMC), and Vinh Long
Province Hospital (VL) in Southern Vietnam from 2002 to 2005. A total of 211 and 418 patients with DHF and DSS,
respectively, diagnosed according to the World Health Organization (WHO) criteria, were analyzed for their characteristic
HLA-A, -B and -DRB1 alleles. Four hundred fifty healthy children (250 from HCMC and 200 from VL) of the same Kinh
ethnicity were also analyzed as population background. In HLA class I, frequency of the HLA-A*24 showed increased
tendency in both DHF and DSS patients, which reproduced a previous study. The frequency of A*24 with histidine at codon
70 (A*2402/03/10), based on main anchor binding site specificity analysis in DSS and DHF patients, was significantly higher
than that in the population background groups (HCMC 02-03 DSS: OR=1.89, P=0.008, DHF: OR=1.75, P=0.033; VL 02-03
DSS: OR=1.70, P=0.03, DHF: OR=1.46, P=0.38; VL 04-05 DSS: OR=2.09, P=0.0075, DHF: OR=2.02, P=0.038). In HLA class
II, the HLA-DRB1*0901 frequency was significantly decreased in secondary infection of DSS in VL 04-05 (OR=0.35,
P=0.0025, Pc=0.03). Moreover, the frequency of HLA-DRB1*0901 in particular was significantly decreased in DSS when
compared with DHF in DEN-2 infection (P=0.02).
Conclusion: This study improves our understanding of the risk of HLA-class I for severe outcome of DV infection in the light
of peptide anchor binding site and provides novel evidence that HLA-class II may control disease severity (DHF to DSS) in
DV infection.
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Introduction
Dengue virus (DV) infection has become one of the most
important mosquito-borne diseases in the tropics [1]. An estimated
50 million people worldwide are infected with DV each year [2].
There are two principal severe forms of DV infection, namely
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS). Other severe forms such as encephalitis and spastic
tetraparesis occur less frequently [3]. Children younger than 15
years of age account for 90% of the severe cases in Southeast Asian
countries [4] where the DHF/DSS incidence has increased about
5 fold more rapidly since 1980 than in the previous 30 years [5].
These severe forms of DV infection have become the leading cause
of death among children in Southern Vietnam [6].
Infection by any of the 4 serotypes of DV, DEN-1, -2, -3, and -
4, may result in no symptoms, dengue fever (DF, without any
serious complications), DHF or DSS. DF is characterized by high
fever; severe headache; retro-orbital, muscle, bone or joint pains;
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leakage near the time of defervescence, thrombocytopenia,
coagulation abnormalities, and hemorrhage. Hypotension with
massive hemorrhage and plasma leakage characterize the most
serious form of DHF called DSS [3]. DHF in this study
corresponds to a milder form of DHF that WHO criteria define
as grade I and II, and DSS to a grade III and IV DHF. The four
criteria in the WHO case definition for DHF (fever, hemorrhage,
thrombocytopenia and plasma leakage) were claimed not so
practical because serious cases sometimes lack one or more of
them, particularly hemorrhage and thrombocytopenia. Instead the
Integrated Management of Childhood Illness (IMCI) has recently
proposed the use of the terms ‘‘dengue’’ and ‘‘severe dengue’’ for
the symptomatic patients with no emphasis on those two signs [7]
The pathogenesis of DHF/DSS is not yet completely understood.
Host immunity has been extensively analyzed, including studies of
antibody-dependent enhancement (ADE) [8], complement activa-
tion [8], anti-platelet antibodies [8], suppressed Th1/predominant
Th2 functions [4] and the production of cytokines [9,10] and
cytotoxic factors [4]. Virus factor has also been studied. DEN-2 viral
strains were associated with DHF/DSS in Thailand and Vietnam;
DEN-3 strains have been predominant in the DHF/DSS in Sri
Lanka, Indonesia and India; while in Latin America, DEN-2,-3,-4
have all been commonly associated with severe disease [8,11]. In
addition to those, still unidentified variations in immune response,
virus virulence, and host genetic background are considered to be
risk factors contributing to disease development [1].
Several genetic factors potentially influencing the severity of
dengue infection, such as vitamin D receptor (VDR), Fcc receptor
II (FccRII), interleukin-4 (IL-4), interleukin-1 receptor antagonist
(IL-1RA), and mannose-binding lectin (MBL) were investigated in
Vietnamese [12]. Among them, the T allele at position 352 of the
VDR gene was associated with resistance to DSS as well as
homozygotes for the arginine variant at position 131 of the FccRII
gene were shown to be protective against DSS. Additionally, the G
allele at position -336 of DC-SIGN (dendritic cell-specific ICAM-3
grabbing nonintegrin) was reported to be protective against DF
among the Thai population [13].
Dengue virus, like other members of the Flaviviridae family,
increases the expression of HLA class I and II molecules on
infected cells [14]. HLA-controlled immune response may be
responsible for the immunopathology of DV infection [14]. The
host HLA allele profile influenced the reactivity of DV-specific T
cells [15,16] however, there have been only a few informative
studies on HLA association with the severity of DV infection
[17,18]. In the present study, we investigated the HLA-A, HLA-B,
and HLA-DRB1 polymorphisms in the Vietnamese population
and the association of HLA alleles with two different clinical forms
of severe DV infection during the years 2002–2005.
Materials and Methods
Study subjects
The study was performed at twohospitals, theChildren’sHospital
No. 2 in Ho Chi Minh City (HCMC) and the Center for Preventive
Medicine inthe Vinh Long Province (VL) of the Mekong Delta.The
enrolment was consecutive sequence of children hospitalized at each
hospital. The inclusion criteria at the entry point in the hospital were
age 6 months to 15 years old, Kinh race, and unrelatedness. The
subjects enrolled initially were 325, 356 and 403 in HCMC 2002–
2003(HCMC02-03),VL2002-2003(VL02-03)andVL2004–2005
(VL 04-05), respectively. DV infection of the patients was diagnosed
by clinical symptoms and history at the admission time. After
hospitalization, the patients were diagnosed by the well established
serology as described below.
WHO classification criteria [3] was applied after a review of
case report form (CRF) of each patient. The DHF classification
required fever or a history of acute fever, bleeding manifestation,
and signs of plasma leakage which include hemoconcentration,
ascites, or pleural effusion with evidence of thrombocytopenia.
Hemoconcentration (more than 20% increase in Hct) was
evaluated by estimating the percent increase in the Hct by
comparing two values recorded at 2 different timings: the
maximum value in defervescence day and the value before
discharge. The ascites, or pleural effusion were detected by
echography or X-ray. The DSS classification required DHF
manifestation plus evidence of clinical hypovolemic shock
(tachycardia and narrow pulse pressure (,20 mmHg))
It was previously reported that the sensitivity of WHO criteria for
DSS in Vietnam was 82%, mainly due to the lack of evidence for
thrombocytopenia [19]. Therefore, we basically followed the WHO
criteria but included patients lacking the significant reduction of
platelet count, which accounted for no more than 11% of all DHF/
DSS cases. Our classification met the requirement of the simplified
classification system of IMCI, which is based on plasma leakage as a
hallmark of severe dengue (DHF/DSS) [7].
Healthy unrelated school children living in HCMC and VL
(250 and 200 subjects respectively) who had no symptoms of
dengue virus infection were collected as a background population
control group for the genetic study. In these control groups, 13
cases (5.2%) in HCMC and 16 cases (8.0%) in VL were
seropositive for IgM ELISA to DV, indicating recent asymptom-
atic DV infection.
This study was approved by the institutional ethical review
committees of the Institute of Tropical Medicine, Nagasaki
University, and the Pasteur Institute in Ho Chi Minh City.
Informed consent was obtained from the parents or legal
guardians of the subjects upon enrollment.
Sample collection and serological diagnosis
Blood samples were collected from patients with suspected
dengue infection at the time of enrolment to the study and in the
Author Summary
Dengue has become one of the most common viral diseases
transmitted by infected mosquitoes (with any of the four
denguevirusserotypes:DEN-1,-2,-3,or-4).Itmaypresentas
asymptomaticorillness,rangingfrommildtosevere disease.
Recently, the severe forms, dengue hemorrhagic fever (DHF)
and dengue shock syndrome (DSS), have become the
leadingcauseofdeath among childreninSouthernVietnam.
The pathogenesis of DHF/DSS, however, is not yet
completely understood. The immune response, virus viru-
lence,andhostgeneticbackgroundareconsideredtoberisk
factors contributing to disease severity. Human leucocyte
antigens (HLA) expressed on the cell surface function as
antigen presenting molecules and those polymorphism can
change individuals’ immune response. We investigated the
HLA-A, -B (class I), and -DRB1 (class II) polymorphism in
Vietnamese children with different severity (DHF/DSS) by a
hospital-based case-control study. The study showed
persons carrying HLA-A*2402/03/10 are about 2 times more
likely to have severe dengue infection than others. On the
other hand, HLA-DRB1*0901 persons are less likely to
develop DSS with DEN-2 virus infection. These results clearly
demonstrated that HLA controlled the susceptibility to
severe forms of DV infection.
HLA-DRB1*0901 and A*24 Affect DHF/DSS
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samples were used for titration of anti-DV IgM and IgG antibodies,
virus isolation, and RT-PCR for determination of viral serotype;
buffy coat samples were used to extract genomic DNA by using the
QIAamp DNA blood kit (Qiagen, Hilden, Germany). DV infection
was defined by previously established serologic criteria for IgM/IgG
ELISAs to DV (DEN 1–4) and Japanese encephalitis virus (kit of
Pasteur Institute HCMC) in paired sera, collected at least three days
interval [20]. IgM and IgG ELISAs were considered positive if the
ratio of optical density (OD) of test sera to OD of negative control
sera was $2.3 [3]. The cases were diagnosed as secondary infection
when DV IgM-to-IgG ratio was ,1.8 [20].
Dengue virus serotyping
Acute plasma samples were inoculated into C6/36 (Aedes
albopictus) cells, the virus was then obtained and the dengue virus
serotype was identified using the direct or indirect fluorescent
antibody technique monoclonal antibodies supplied by the Centers
for Disease Control and Prevention (Fort Collins, CO, USA) [21].
Viral RNA was also extracted from the same acute plasma samples
with the QIAamp Viral RNA Mini Kit (Qiagen, Hilden,
Germany) for detection of DV and confirmation of its serotype
as described [21]. Briefly, cDNA from the DV genome RNA was
amplified with the Ready-to-go RT-PCR test kit (Amersham, MA,
USA) using consensus primer set (D1 and D2) [22]. Then, the
serotype was determined by semi-nested PCR to amplify serotype-
specific fragments from the regions encoding the capsid and
membrane proteins of DV using the specific primer sets (TS1,
TS2, TS3, and TS4) [22].
HLA typing
HLA-A, -B and -DRB1 were typed by using LABType SSO
class I A and B and class II DRB1 locus kits (One Lambda, CA,
USA) and the Luminex LX 100 IS system (Hitachi, Japan). IS 2.3
typing software (Luminex Corporation, TX, USA) was used to
determine the genotype. The presence of alleles of interest were
confirmed by PCR with sequence-specific primers (PCR-SSP) [23]
(HLA-A*24) and sequencing-based typing (HLA-DRB1*0901)
[according to the standard protocol 10-B of the 13th International
Histoconpatibility Workshop (http://www.ihwg.org/protocols/
sbt/sbtprot.htm)]. HLA-A, HLA-B, and HLA-DRB1 genotype
distributions were checked with Hardy-Weinberg equilibrium.
Statistical analysis
The frequencies of individuals carrying particular alleles
(phenotype frequencies) were compared between categories of
the case group (DHF or DSS) and the population background
group. The difference in frequency was evaluated by the odds ratio
(OR) with Fisher exact 95% confidence intervals (95% CI), and
Exact Fisher two sided P using StatsDirect statistical software,
version 2.6.4. The locus-wise correction of the P value (Pc) for
multiple tests was made by multiplying the P value by the number
of the major alleles whose phenotype frequencies were more than
5% in either the patient or population background group. The
correction factors (CF) were 8 for HLA-A, 13 for HLA-B and 12
for HLA-DRB1. Difference yielding Pc values less than 0.05 was
considered statistically significant.
Results/Discussion
Clinical features of the patients
Demographic and clinical features of the study subjects are shown
in Table 1. An important clinical findings in this study was
hepatomegaly which was clearly more prevalent in DSS than in
DHF patients (in HCMC 02-03: 90.8% vs. 47.9%, in VL 02-03:
98.8% vs. 88.6%, and in VL 04-05: 93.8% vs. 78.0%, ORs above 4,
footnote b of Table 1). There was substantial evidence of
hepatomegaly inAsian patients [24,25] as well asinSouth American
patients [26] with DHF/DSS. Our results therefore agree with the
previous study by Pham et al. which propose hepatomegaly as one of
the clinical predictors of DSS in children [27].
Another point of note was concerning the issue of significance of
secondary infection of DV in the pathogenesis of severe cases.
Although secondary infection has been reported to confer most of
the risk of disease severity, it is also known that patients without
evidence of secondary infection substantially contribute to severe
cases in Taiwan [28] and Thailand [29]. Our study is similar to
that study in Thailand 2003 [29], where the patients with high
IgM/IgG ratio consist of nearly 60% of DSS and 40% of DHF.
The data still support the notion of disease risk associated with
secondary infection (footnote c of Table 1).
It is worth to mention that four percents of our patients were
under 1 year of age and all had primary DV infection. The
presence of non neutralizing or low level of neutralizing maternal
antibodies may play a role in the development of severe disease.
Halstead et al. pointed out that infants are a high risk group for
Table 1. Study subjects
Ho Chi Minh City (HCMC) Vinh Long province (VL)
HCMC 02-03 VL02-03 VL04-05
DSS DHF Controls DSS DHF DSS DHF Control
n=152 n=117 n=250 n=170 n=35 n=96 n=59 n=200
Mean age (years)6SD 9.163.2 10.663.2 7.864.4 9.963.0 8.664.2 8.663.4 8.864.2 10.962.2
Male (%)
a 80 (52.6) 70 (59.8) 143 (57.0) 78 (45.9) 16 (45.7) 37 (38.5) 36 (61.0) 110 (55.0)
Hepatomegaly (%)
b 138 (90.8) 56 (47.9) nd 168 (98.8) 31 (88.6) 90 (93.8) 46 (78.0) nd
Percent increase in Hct (%)6SD 36.6616.5 27.469.8 nd 34.5620.9 31.2617.2 26619.9 23.367.7 nd
Secondary infection (%)
c 81 (53.3) 50 (42.7) nd 95 (55.9) 13 (37.1) 80 (83.3) 46 (78.0) nd
DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome, SD: standard deviation, nd: not done, P: Fisher’s exact test, Hct: hematocrit.
aMale among DSS patients in VL04-05 vs. VL controls: P=0.008
bHepatomegaly among DSS patients vs. DHF patients, in HCMC 02-03: OR=10.74, P,0.0001, in VL 02-03: OR=10.84, P=0.008, in VL 04-05:OR=4.24, P=0.005
cSecondary infection in DSS VL04-05 vs. HCMC 02-03: P,0.0001, VL04-05 vs. VL02-03: P,0.0001 and in DHF VL04-05 vs. HCMC 02-03: P,0.0001, VL04-05 vs. VL02-03:
P=0.0001
doi:10.1371/journal.pntd.0000304.t001
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dengue infection [30].
DV serotypes and disease severity
Virus serotype was tested on 388 patients whose blood samples
collected within five days after the onset of symptoms, mostly on
days 4 and 5. As shown in Table 2, DV was identified in 87 DHF/
DSS patients, which gave a detection rate of 22.4%. This was far
lower than many other studies but consistent with a previous
observation that the sensitivity to detect DV is dulled in the present
of neutralizing antibody [20]. Similar low detection rate was
reported in Bangladesh study in 2002 [31], where virus serotype
could only be identified in 8% of samples.
DEN-2 constituted the majority of the total isolates, 50 (57.5%)
followed by 16 DEN-1 (18.4%), 13 DEN-3 (14.9%) and 8 DEN-4
(9.2%). The correlation between DEN-2 infection and the severe
clinical forms (Table 2) provided additional proof for higher
virulence of this serotype because previous study reported that
patients with DEN-2 had a larger pleural effusion index than those
infected by other virus serotypes [32].
Phenotype frequencies of HLA-A, HLA-B and HLA-DRB1
We identified 16 HLA-A alleles, 47 HLA-B alleles and 36 HLA-
DRB1 alleles in the study subjects. Major alleles (phenotype
frequencies having more than 5% in either the patient or healthy
background groups) are shown in Table 3 and Table S1,
accounted for about 80–90% of the total phenotypes. We analyzed
only these major alleles for the evaluation of the risk of disease
severity because rare alleles would have little impact on population
risk. There were no significant difference in phenotype frequencies
of the major alleles in the 2 population background groups (Table
S1), and these data were compatible with data from a previous
study [17] on the same Kinh ethnic in Southern Vietnam.
HLA-A*24 was positively associated with DSS or DHF
As shown in Table 4 and 5, HLA-A*24 increased in frequency
among DHF and DSS patients when compared with the control in
all 3 sample groups, HCMC 02-03 (DSS: OR=1.62, P=0.04,
Pc=0.3; DHF: OR=1.35, P=0.26), VL 02-03 (DSS: OR=1.51,
P=0.08; DHF: OR=1.34, P=0.4), and VL 04-05 (DSS:
OR=1.80, P=0.029, Pc=0.2; DHF: OR=2.71, P=0.0019,
Pc=0.02).
Certain alleles of the HLA-class I genes were previously found
to be associated with DHF or DSS [1]. In a study of Thai patients,
Stephens et al. found that HLA- A*0207 and HLA-B*51 were
susceptible to both DHF and DSS [18]. It was also reported that
HLA-A*29 and A*33 were protective against DHF and DSS in
Cuban [33] and in Vietnamese patients, respectively [17]. The
Table 2. Dengue virus serotypes and disease severity (2002–
05)
Number of cases (%) DSS vs. DHF
DSS (n=43) DHF (n=44) OR (95% CI) P
DEN-1 10 (23.3) 6 (13.6) 1.90 (0.56–7.11) 0.3
DEN-2 30 (70.0) 20 (45.5) 2.77 (1.05–7.37) 0.03
DEN-3 3 (7.0) 10 (22.7) 0.26 (0.04–1.11) 0.07
DEN-4 0 (0.0) 8 (18.2) 0.05 (0.003–0.88) 0.006
DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome
OR: Odds ratio, 95% CI: Fisher exact 95% confidence intervals, P: Fisher’s exact
test
doi:10.1371/journal.pntd.0000304.t002
Table 3. Major alleles of HLA-A, -B, -DRB1 in Vietnamese
HLA Allele Total
HLA-A *01, *02, *11, *24, *26, *29, *30, *33 8
HLA-B *07, *13, *15, *27, *35, *38, *40, *44, *46, *51, *55, *57,
*58
13
HLA-DRB1 *0301, *0403, *0405, *0701, *0803, *0901, *1001, *1202,
*1401, *1501, *1502 *1602
12
doi:10.1371/journal.pntd.0000304.t003
Table 4. Phenotype frequencies of HLA-A*24 and HLA-DRB1*0901 in primary and secondary infection and population background
groups
Phenotype HCMC VL
HCMC 02-03 VL 02-03 VL 04-05
DSS DHF Control DSS DHF DSS DHF Control
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
1. HLA-A*24
1.1 A*24 53 (34.9) 36 (30.8) 62 (24.8) 57 (33.5) 11 (31.4) 36 (37.5) 28 (47.5) 50 (25.0)
1.2 A*24 Primary infection 28 (39.4) 25 (37.3) 62 (24.8) 28 (37.3) 8 (36.4) 3 (18.8) 7 (58.3) 50 (25.0)
1.3 A*24 Secondary infection 25 (30.9) 11 (22.0) 62 (24.8) 29 (30.5) 3 (23.0) 33 (41.3) 21 (45.7) 50 (25.0)
2. HLA- DRB1*0901
2.1 DRB1*0901 33 (21.7) 31 (26.5) 61 (24.4) 35 (20.6) 6 (17.1) 14 (14.6) 15 (25.4) 63 (31.5)
2.2 DRB1*0901 Primary
infection
15 (21.1) 18 (26.9) 61 (24.4) 17 (22.7) 2 (9.1) 3 (18.8) 4 (33.3) 63 (31.5)
2.3 DRB1*0901 Secondary
infection
18 (22.2) 13 (26.0) 61 (24.4) 18 (18.9) 4 (30.8) 11 (13.8) 11 (23.9) 63 (31.5)
DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome
doi:10.1371/journal.pntd.0000304.t004
HLA-DRB1*0901 and A*24 Affect DHF/DSS
www.plosntds.org 4 October 2008 | Volume 2 | Issue 10 | e304inconsistency of these HLA associations may be the result of the
differences in ethnicity, geographic location or the diversity of the
predominant virus during the study periods [2,34].
The results of HLA class I association from the present study
reproduced a previous Vietnamese study (309 cases and 251
controls) by Loke et al. in which HLA-A*24 association with DHF
and DSS was found, with OR 1.54 and P value 0.021 [17].
Considering such reproducibility in different study periods, within
the same ethnic group and in the same region, give us the
confidence to assign an association of HLA-A*24 and DHF, DSS
even though our P value just reached the significant level before
Bonferoni correction.
HLA-A*24 with Histidine at codon 70 was positively
associated with DSS and DHF
It is known that HLA-A*24 alleles fall into at least two subtypes
by the difference at codon 70 of alpha 1 domain, which together
with codons 9, 45, 63, 66 and 67 composes peptide binding pocket
B for P2 anchor position [35]. In the present study, there were 4
different A*24 alleles, A*2402, A*2403, A*2407 and A*2410
(Table 6). A*2407 is different from the others at codon 70 where
histidine (CAC) is changed to glutamine (CAG). The frequencies of
A*24 with histidine at codon 70 in DSS and DHF patients were
significantly higher than that in the population background groups
(HCMC 02-03 DSS: OR=1.89, P=0.008, DHF: OR=1.75,
Table 5. Association of HLA-A*24, -DRB1*0901 allele with severe forms
HCMC VL
HCMC 02-03 VL 02-03 VL 04-05
OR (95% CI) P Pc OR (95% CI) P Pc OR (95% CI) P Pc
1. HLA- A*24
1.1 DSS vs. control 1.62 (1.02–2.58) 0.04 0.3 1.51 (0.94–2.44) 0.084 - 1.80 (1.03–3.13) 0.029 0.2
1.2 DSS with primary infection vs. controls 1.97 (1.08–3.56) 0.024 0.2 2.38 (1.30–4.32) 0.0032 0.03 0.69 (0.12–2.67) 0.77 -
1.3 DSS with secondary infection vs. controls 1.35 (0.74–2.42) 0.3 - 1.76 (0.99–3.09) 0.045 0.36 2.11 (1.17–3.77) 0.009 0.07
1.4 DHF vs. control 1.35 (0.80–2.25) 0.26 - 1.34 (0.57–3.16) 0.4 - 2.71 (1.41–5.16) 0.0019 0.02
1.5 DHF with primary infection vs. controls 1.13 (0.63–2.00) 0.67 - 2.29 (0.78–6.20) 0.1 - 4.2 (1.08–17.43) 0.018 0.1
1.6 DHF with secondary infection vs. controls 0.86 (0.37–1.83) 0.7 - 1.20 (0.20–4.89) 0.73 - 2.52 (1.22–5.13) 0.007 0.056
1.7 DSS vs. DHF 1.20 (0.70–2.09) 0.51 - 1.1 (0.48–2.67) 1 - 0.66 (0.33–1.35) 0.24 -
2. HLA- DRB1*0901
2.1 DSS vs. control 0.86 (0.51–1.42) 0.63 - 0.56 (0.34–0.93) 0.018 0.2 0.37 (0.18–0.72) 0.0018 0.02
2.2 DSS with primary infection vs. controls 0.83 (0.41–1.62) 0.64 - 0.64 (0.32–1.22) 0.18 - 0.50 (0.09–1.92) 0.4 -
2.3 DSS with secondary infection vs. controls 0.89 (0.46–1.66) 0.77 - 0.51 (0.26–0.95) 0.026 0.3 0.35 (0.16–0.72) 0.0025 0.03
2.4 DHF vs. control 1.12 (0.65–1.90) 0.69 - 0.45 (0.15–1.18) 0.10 - 0.74 (0.36–1.48) 0.42 -
2.5 DHF with primary infection vs. controls 1.14 (0.58–2.17) 0.75 - 0.22 (0.02–0.95) 0.027 0.3 1.09 (0.23–4.24) 1 -
2.6 DHF with secondary infection vs. controls 1.09 (0.50–2.26) 0.86 - 0.97 (0.21–3.63) 1 - 0.68 (0.29–1.49) 0.37 -
2.7 DSS vs. DHF 0.77 (0.42–1.41) 0.39 - 1.25 (0.46–3.98) 0.82 - 0.50 (0.20–1.23) 0.14 -
DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome, OR: Odds ratio, 95% CI: Fisher exact 95% confidence intervals, P: Fisher’s exact test, Pc: corrected P.
doi:10.1371/journal.pntd.0000304.t005
Table 6. Phenotype frequencies of HLA-A*24 subgroups
A*24 HCMC VL
HCMC 02-03 VL 02-03 VL 04-05
DSS DHF Control DSS DHF DSS DHF Control
No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
1. A*24 with histidine at codon 70
A*2402 46 (30.3) 34 (29.1) 43 (17.2) 53 (31.2) 8 (22.9) 34 (35.4) 18 (30.5) 38 (19.0)
A*2403 0 (0.0) 1 (0.9) 2 (0.8) 1 (0.6) 1 (2.9) 1 (1.0) 2 (3.4) 1 (0.5)
A*2410 2 (0.0) 0 (0.0) 4 (0.8) 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.7) 4 (2.0)
Total 48 (31.6) 35 (29.9) 49 (19.6) 54 (31.8) 10 (28.6) 35 (35.5) 21 (35.6) 43 (21.5)
2. A*24 with glutamine at codon 70
A*2407 5 (3.3) 2 (1.7) 13 (5.2) 3 (1.8) 1 (2.9) 1 (1.0) 7 (11.9) 9 (4.5)
DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome
doi:10.1371/journal.pntd.0000304.t006
HLA-DRB1*0901 and A*24 Affect DHF/DSS
www.plosntds.org 5 October 2008 | Volume 2 | Issue 10 | e304P=0.03; VL 02-03 DSS: OR=1.70, P=0.03, DHF OR=1.46,
P=0.38; VL 04-05 DSS: OR=2.09, P=0.0075, DHF OR=2.02,
P=0.038, Table 7). On the other hand, A*24 with glutamine at
codon 70, A*2407 in our samples, did not show any significant
difference in frequency (Table 6). Similar behavior of this allele was
documented in Indian HIV study [36].
The association of HLA-A*24 in the VL 04-05 samples was
stronger than in VL 02-03 and HCMC 02-03, possibly due to
higher secondary infection rate in the VL 04-05 samples. Memory
T cells might be important in the A*24 associated pathogenesis of
DHF/DSS. HLA-A*24 is reported to be one of the potential
restricting alleles for NS3 dengue viral protein and CTLs
recognizing NS3 peptides coupled with HLA-A*24 were cross-
reactive between serotypes because NS3 is highly conserved [37].
Two previous Vietnamese studies reported an identification of the
DEN-2 NS3 556–564 peptide that was restricted by HLA-A*24
[17,38], but further study is needed to clarify the role of A*24-
restricted CD8 T-cells in the pathogenesis of DHF/DSS.
HLA-DRB1*0901 was negatively associated with DSS
As shown in Table 4 and 5, the HLA-DRB1*0901 allele
significantly decreased in frequency in DSS patients in VL 04-05
(OR=0.37, P=0.0018, Pc=0.02) when compared to the control,
mainly in secondary infection (OR=0.35, P=0.0025, Pc=0.03),
not in primary infection. This trend was also observed in the other
2 groups of samples but did not reach statistical significance (VL
02-03: OR 0.51, P=0.026, Pc=0.3; HCMC 02-03: OR=0.89,
P=0.77).
Certain HLA class II alleles have been reported to confer a
protectiveeffectininfectionsofhumanimmunodefiencyvirus(HIV),
hepatitis C virus (HCV), and hepatitis B virus (HBV) [39]. In dengue
virus infection, protective DRB1*07 and DRB1*04 alleles were
recently reported. DRB1*07 was protective against DF, DHF and
DSS and DRB1*04 was protective against secondary DF in Cuban
population [34], DHF or DSS in Mexican population [40]. Possibly
there is a common primary associated gene closely located to DRB1
locus, such as HLA-DQB1 and HLA-DRB4, for those alleles
(DRB1*07 and DRB1*04) and Vietnamese DRB1*0901. One of the
most frequent haplotypes among Oriental populations (including
Kinh ethnic) is DRB1*0901-DQB1*030302. DQB1*030302 is also
reported to be in disequilibrium with DRB1*0701 [41], however
there was no reduced frequency of DRB1*0701 in DSS patients
compared to controls in our data. Furthermore, haplotypes found in
South America are DRB1*0701-DQB1*0201 and HLA-
DRB1*0403-DQB1*0302, not DQB1*030302, which suggests that
the association of these protective alleles could not be elucidated by a
common DQB1 allele. The possibility of primary disease-protective
association with DRB4*01 (encoding DR53 sero-specificity) remains
to be examined because of DRB4*01 haplotypic association with
DRB1*07, *04 and *0901 was found in all populations which have
been studied [42], although neither DRB1*07 or DRB1*04
exhibited difference in frequency in our samples.
Protective effect of HLA-DRB1*0901 against DSS
development from DHF was evident when having DEN-2
infection
To see the effect of virus serotype on the HLA susceptibility, we
analyzed the HLA alleles in the DEN-2-positive patients and those
that were positive for DEN-1, DEN-3, or DEN-4 (DEN-2-negative).
As shown in Table 8, HLA-DRB1*0901 frequency was significantly
decreased in DSS compared with DHF among DEN-2- positive
patients (OR=0.13, P=0.02). The effect of DRB1*0901 appeared
to be DEN-2 specific because DEN-2-negative population did not
show significant difference, although this may be due to the small
sample size as Breslow-Day statistic for the uniformity of odds ratio
did not reach significant level (P=0.14).
The HLA-DRB1*0901 allele has also been reported at higher
frequency in noncirrhotic HCV patients than in patients with
cirrhosis [43,44], suggesting protective effect of this allele against
tissue destruction and disease progression. Here, when we focus on
DEN-2 infection, a higher frequency of HLA-DRB1*0901 in DHF
than in DSS patients was found. The protective effect of this allele
against DSS development from DHF could be considered as a new
finding in dengue infection. It is generally believed that DSS is
preventable by intense clinical management, in fact a certain
number of patients, however fall to shock in spite of the early efforts
of physicians. Although the pathogenesis of DHF/DSS is still
unclear, clinical studies have suggested that the host immune
response shifted to Th2 dominant in most DSS cases [45]. Because
Table 7. Association of HLA-A*24 with histidine at codon 70 and severe forms of DV infection
HCMC VL
HCMC 02-03 VL 02-03 VL 04-05
OR (95% CI) P OR (95% CI) P OR (95% CI) P
DSS vs. control 1.89 (1.16–3.09) 0.008 1.70 (1.04–2.79) 0.03 2.09 (1.18–3.70) 0.0075
DHF vs. control 1.75 (1.02–2.98) 0.033 1.46 (0.58–3.44) 0.38 2.02 (1.01–3.95) 0.038
DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome, OR: Odds ratio, 95% CI: Fisher exact 95% confidence intervals, P: Fisher’s exact test. This analysis was
perform after the confirmation of A
*24 association, so that the correction of P value did not apply.
doi:10.1371/journal.pntd.0000304.t007
Table 8. Phenotype frequency of HLA- DRB1*0901 allele in
DHF or DSS patients with DEN-2 or other serotypes
Serotype DSS DHF DSS vs. DHF P
No. (%) No. (%) OR (95% CI)
DEN-2 (+) n=30 n=20
DRB1*0901 (+) 2 (6.7) 7 (35.0) 0.13 (0.01–0.86) 0.02
DRB1*0901 (2) 28 (93.3) 13 (65.0)
DEN-2 (2) n=13 n=24
DRB1*0901 (+) 3 (23.1) 7 (29.2) 0.73 (0.10–4.22) 1
DRB1*0901 (2) 10 (76.9) 17 (70.8)
DHF: dengue hemorrhagic fever, DSS: dengue shock syndrome,
DEN-2 (2): consisted of DEN-1, DEN-3, and DEN-4 as shown in Table 2.
OR: Odds ratio, 95%CI: Fisher exact 95% confidence intervals, P: Fisher’s exact
test.
doi:10.1371/journal.pntd.0000304.t008
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response, it is probable that patients with HLA-DRB1*0901 may be
prevented from the shift toward Th2 dominance. Further studies are
needed to clarify this point.
In conclusion, our study confirmed the previous reported HLA
association between HLA-A*24 and DHF or DSS and moreover
showed that A*24 with Histidine at codon 70 to be susceptible to
DSS and DHF, and HLA-DRB1*0901 to be protective against the
development of DSS, particularly in patients with DEN-2
infection. This study represents another attempt to improve our
understanding of the risk of HLA-class I for severe outcome of DV
infection in the light of peptide anchor binding site and provides a
novel evidence that HLA-class II may control disease severity
(DHF to DSS) in DV infection.
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